Established at the Montreal Heart Institute, MONOGENIC has an experienced management team supported by leading scientific and clinical experts in the field of PCSK9, lipid metabolism and ASCVD.



​MONOGENIC Pharmaceuticals is developing innovative and disruptive orally available small molecules to control atherosclerotic cardiovascular disease (ASCVD) by helping the body to clear excess LDL-Cholesterol.


Over 20 million person-years of follow-up and over 150 000 cardiovascular events unequivocally demonstrated a direct causal link between LDL-Cholesterol and ASCVD.


MONOGENIC is grateful to the Montreal Heart Institute as its institutional partner.

We are currently seeking for private partners to complete our Series A and R&D Program  (pre-IND and Phase 1) with interest in advancing to and completion of Phase 2.